Skip to main content
Top
Published in: Annals of Hematology 7/2008

01-07-2008 | Original Article

Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions

Authors: Nathalie Douet-Guilbert, Audrey Basinko, Frédéric Morel, Marie-Josée Le Bris, Valérie Ugo, Patrick Morice, Christian Berthou, Marc De Braekeleer

Published in: Annals of Hematology | Issue 7/2008

Login to get access

Abstract

Deletion of the long arm of chromosome 20 is a recurrent abnormality observed in myelodysplastic syndromes (MDS) and in Philadelphia-chromosome-negative myeloproliferative disorders (MPD). Our objective was to characterize the deletion size among 38 MDS and MPD patients using fluorescence in situ hybridization (FISH) with bacterial artificial chromosome (BAC) probes and to define commonly deleted and retained regions on chromosome 20. Patients were distributed in three groups according to the World Health Organization classification: MDS (22 patients), MPD (12 patients) and myelodysplastic/myeloproliferative diseases (four patients). FISH with centromeric, subtelomeric, and unique sequence probes was performed to characterize the deletion whereas its size was delineated using BAC clones. All 38 deletions were found to be interstitial. A commonly deleted region was identified for each of the three groups; it varied from 6.62 to 10.4 Mb and showed considerable overlapping. Two commonly retained regions (CRR), also showing overlapping, were identified in all three groups, one in the centromeric region, the other in the telomeric region. The deletion size is highly variable, with no apparent recurrent breakpoint. The deletion may result in the loss of one or several tumor suppressor genes but the target genes remain unknown. Loss of genes plays an important part in the myeloid leukemic process associated with del(20q). However, genes located in the retained chromosomal regions may also play a role in the oncogenetic mechanisms.
Literature
1.
go back to reference Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60:507–516PubMed Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60:507–516PubMed
2.
go back to reference Rege-Cambrin G, Mecucci C, Tricot G, Michaux JL, Louwagie A, Van Hove W, Francart H, Van den Berghe H (1987) A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233–245PubMedCrossRef Rege-Cambrin G, Mecucci C, Tricot G, Michaux JL, Louwagie A, Van Hove W, Francart H, Van den Berghe H (1987) A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233–245PubMedCrossRef
3.
go back to reference Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 11:819–848PubMedCrossRef Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 11:819–848PubMedCrossRef
4.
go back to reference Testa JR, Kanofsky JR, Rowley JD, Baron JM, Vardiman JW (1981) Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol 11:29–45PubMedCrossRef Testa JR, Kanofsky JR, Rowley JD, Baron JM, Vardiman JW (1981) Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol 11:29–45PubMedCrossRef
5.
go back to reference Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Deminatti M, Bauters F (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855–859PubMed Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Deminatti M, Bauters F (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855–859PubMed
6.
go back to reference Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M (2007) Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 173:57–62PubMedCrossRef Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M (2007) Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 173:57–62PubMedCrossRef
7.
go back to reference Brigaudeau C, Liozon E, Bernard P, Trimoreau F, Bordessoule D, Praloran V (1996) Deletion of chromosome 20q associated with hypereosinophilic syndrome. Cancer Genet Cytogenet 87:82–84PubMedCrossRef Brigaudeau C, Liozon E, Bernard P, Trimoreau F, Bordessoule D, Praloran V (1996) Deletion of chromosome 20q associated with hypereosinophilic syndrome. Cancer Genet Cytogenet 87:82–84PubMedCrossRef
8.
go back to reference Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302PubMedCrossRef Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302PubMedCrossRef
9.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMed
10.
go back to reference Murphy S (1999) Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36:9–13PubMed Murphy S (1999) Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36:9–13PubMed
11.
go back to reference Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, De Braekeleer M (2007) Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 78:457–467PubMedCrossRef Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, De Braekeleer M (2007) Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 78:457–467PubMedCrossRef
12.
go back to reference ISCN (2005) An international system for human cytogenetic nomenclature. Karger, Basel ISCN (2005) An international system for human cytogenetic nomenclature. Karger, Basel
13.
go back to reference Pinson L, Perrin A, Plouzennec C, Parent P, Metz C, Collet M, Le Bris MJ, Douet-Guilbert N, Morel F, De Braekeleer M (2005) Detection of an unexpected subtelomeric 15q26.2→qter deletion in a litte girl: clinical and cytogenetic studies. Am J Med Genet 138:160–165CrossRef Pinson L, Perrin A, Plouzennec C, Parent P, Metz C, Collet M, Le Bris MJ, Douet-Guilbert N, Morel F, De Braekeleer M (2005) Detection of an unexpected subtelomeric 15q26.2→qter deletion in a litte girl: clinical and cytogenetic studies. Am J Med Genet 138:160–165CrossRef
14.
go back to reference Davis MP, Dewald GW, Pierre RV, Hoagland HC (1984) Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 12:63–71PubMedCrossRef Davis MP, Dewald GW, Pierre RV, Hoagland HC (1984) Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 12:63–71PubMedCrossRef
15.
go back to reference Le Beau MM, Westbrook CA, Diaz MO, Rowley JD (1985) c-src is consistently conserved in the chromosomal deletion (20q) observed in myeloid disorders. Proc Natl Acad Sci USA 82:6692–6696PubMedCrossRef Le Beau MM, Westbrook CA, Diaz MO, Rowley JD (1985) c-src is consistently conserved in the chromosomal deletion (20q) observed in myeloid disorders. Proc Natl Acad Sci USA 82:6692–6696PubMedCrossRef
16.
go back to reference Roulston D, Espinosa RI, Stoffel M, Bell GI, Le Beau MM (1993) Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82:3424–3429PubMed Roulston D, Espinosa RI, Stoffel M, Bell GI, Le Beau MM (1993) Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82:3424–3429PubMed
17.
go back to reference Asimakopoulos FA, White NJ, Nacheva E, Green AR (1994) Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84:3086–3094PubMed Asimakopoulos FA, White NJ, Nacheva E, Green AR (1994) Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84:3086–3094PubMed
18.
go back to reference Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JGR, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR (1998) A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the commonly deleted segment. Genomics 49:351–362PubMedCrossRef Bench AJ, Aldred MA, Humphray SJ, Champion KM, Gilbert JGR, Asimakopoulos FA, Deloukas P, Gwilliam R, Bentley DR, Green AR (1998) A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the commonly deleted segment. Genomics 49:351–362PubMedCrossRef
19.
go back to reference Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJP, Campbell LJ, Bentley DR, Deloukas P, Green AR (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG) Oncogene 19:3902–3913PubMedCrossRef Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJP, Campbell LJ, Bentley DR, Deloukas P, Green AR (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG) Oncogene 19:3902–3913PubMedCrossRef
20.
go back to reference Wang PW, Eisenbart JD, Espinosa RI, Davis EM, Larson RA, Le Beau MM (2000) Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 68:28–32CrossRef Wang PW, Eisenbart JD, Espinosa RI, Davis EM, Larson RA, Le Beau MM (2000) Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 68:28–32CrossRef
21.
go back to reference Wang PW, Iannantuoni K, Davis EM, Espinosa R III, Stoffel M, Le Beau MM (1998) Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes, Chromosomes & Cancer 21:75–81CrossRef Wang PW, Iannantuoni K, Davis EM, Espinosa R III, Stoffel M, Le Beau MM (1998) Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes, Chromosomes & Cancer 21:75–81CrossRef
22.
go back to reference MacGrogan D, Alvarez S, DeBlasio T, Jhanwar S, Nimer SD (2001) Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150–4160PubMedCrossRef MacGrogan D, Alvarez S, DeBlasio T, Jhanwar S, Nimer SD (2001) Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 20:4150–4160PubMedCrossRef
23.
go back to reference Koga H, Matsui S, Hirota T, Takebayashi S, Okumura K, Saya H (1999) A human homolog of Drosophila lethal(3)malignant brain tumor (l(3)mbt) protein associates with condensed mitotic chromosomes. Oncogene 18:3799–3809PubMedCrossRef Koga H, Matsui S, Hirota T, Takebayashi S, Okumura K, Saya H (1999) A human homolog of Drosophila lethal(3)malignant brain tumor (l(3)mbt) protein associates with condensed mitotic chromosomes. Oncogene 18:3799–3809PubMedCrossRef
24.
go back to reference Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR (2004) Imprinting of the human L3MBTL gene, a polycomb family mamver located in region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci USA 101:7341–7346PubMedCrossRef Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR (2004) Imprinting of the human L3MBTL gene, a polycomb family mamver located in region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci USA 101:7341–7346PubMedCrossRef
25.
go back to reference MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B, Nimer SD (2004) Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes, Chromosomes & Cancer 4:203–213CrossRef MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B, Nimer SD (2004) Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes, Chromosomes & Cancer 4:203–213CrossRef
26.
go back to reference Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, Guo S, Feng X, Su K, Mao Y, Cheng S, Gao Y (2006) Expression of targeting protein for Xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res 12:1121–1127PubMedCrossRef Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, Guo S, Feng X, Su K, Mao Y, Cheng S, Gao Y (2006) Expression of targeting protein for Xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res 12:1121–1127PubMedCrossRef
27.
go back to reference Mackinnon RN, Patsouris C, Chudoba I, Campbell LJ (2007) A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes. Genes, Chromosomes & Cancer 46:27–36CrossRef Mackinnon RN, Patsouris C, Chudoba I, Campbell LJ (2007) A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes. Genes, Chromosomes & Cancer 46:27–36CrossRef
28.
go back to reference Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef
29.
go back to reference Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY (2005) Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 124:282–287PubMedCrossRef Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY (2005) Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 124:282–287PubMedCrossRef
30.
go back to reference Garcia-Domingo D, Ramirez D, Gonzalez DB, Martinez A (2003) Death inducer-obliterator I triggers apoptosis after nuclear translocation and caspase upregulation. Mol Cell Biol 23:3216–3225PubMedCrossRef Garcia-Domingo D, Ramirez D, Gonzalez DB, Martinez A (2003) Death inducer-obliterator I triggers apoptosis after nuclear translocation and caspase upregulation. Mol Cell Biol 23:3216–3225PubMedCrossRef
31.
go back to reference Futterer A, Campanero MR, Leonardo E, Criado LM, Flores JM, Hernandez JM, San Miguel JF, Martinez AC (2005) Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 115:2351–2362PubMedCrossRef Futterer A, Campanero MR, Leonardo E, Criado LM, Flores JM, Hernandez JM, San Miguel JF, Martinez AC (2005) Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 115:2351–2362PubMedCrossRef
32.
go back to reference Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J (2005) Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37:977–990PubMedCrossRef Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J (2005) Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37:977–990PubMedCrossRef
33.
go back to reference Gilley D, Tanaka H, Herbert BS (2005) Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 37:1000–1013PubMedCrossRef Gilley D, Tanaka H, Herbert BS (2005) Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 37:1000–1013PubMedCrossRef
34.
go back to reference De Lange T (1995) Telomere dynamics and genome instability in human cancer. In: Blackburn EH, Greider CW (eds) Telomeres. Cold Spring Harbor, Plainview, NY, pp 265–293 De Lange T (1995) Telomere dynamics and genome instability in human cancer. In: Blackburn EH, Greider CW (eds) Telomeres. Cold Spring Harbor, Plainview, NY, pp 265–293
35.
go back to reference Murnane JP, Sabatier L (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays 26:1164–1174PubMedCrossRef Murnane JP, Sabatier L (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays 26:1164–1174PubMedCrossRef
36.
go back to reference Sabatier L, Ricoul M, Pottier G, Murnane JP (2005) The loss of a single telomere can result in instability of multiple chromosomes in a human tumor cell line. Mol Cancer Res 3:139–150PubMedCrossRef Sabatier L, Ricoul M, Pottier G, Murnane JP (2005) The loss of a single telomere can result in instability of multiple chromosomes in a human tumor cell line. Mol Cancer Res 3:139–150PubMedCrossRef
37.
go back to reference Fenaux P, Morel P, Lai JL (1996) Cytogenetics of myelodysplastic syndromes. Semin Hematol 33:127–138PubMed Fenaux P, Morel P, Lai JL (1996) Cytogenetics of myelodysplastic syndromes. Semin Hematol 33:127–138PubMed
38.
go back to reference Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P (1998) Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83:258–275PubMedCrossRef Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P (1998) Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83:258–275PubMedCrossRef
39.
go back to reference Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohyashiki K (2006) Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171:9–16PubMedCrossRef Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohyashiki K (2006) Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171:9–16PubMedCrossRef
40.
go back to reference Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International socring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International socring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
41.
go back to reference Brezinova J, Zemanova Z, Ransdorfova S, Sindelarova L, Siskova M, Neuwirtiva R, Cermak J, Michalova K (2005) Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160:188–192PubMedCrossRef Brezinova J, Zemanova Z, Ransdorfova S, Sindelarova L, Siskova M, Neuwirtiva R, Cermak J, Michalova K (2005) Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160:188–192PubMedCrossRef
42.
go back to reference Ohyashiki K, Murakami T, Ohyashiki JH, Kodama A, Sakai N, Ito H, Toyama K (1992) Double 20q−Anomaly in myelodysplastic syndrome. Cancer Genet Cytogenet 58:174–176PubMedCrossRef Ohyashiki K, Murakami T, Ohyashiki JH, Kodama A, Sakai N, Ito H, Toyama K (1992) Double 20q−Anomaly in myelodysplastic syndrome. Cancer Genet Cytogenet 58:174–176PubMedCrossRef
43.
go back to reference Kubonishi I, Muneishi H, Hashimoto E, Hatakeyama N, Kuzume T, Miyoshi I (1996) Duplication of del(20)(q11) in a case of MDS. Cancer Genet Cytogenet 86:185–186PubMedCrossRef Kubonishi I, Muneishi H, Hashimoto E, Hatakeyama N, Kuzume T, Miyoshi I (1996) Duplication of del(20)(q11) in a case of MDS. Cancer Genet Cytogenet 86:185–186PubMedCrossRef
44.
go back to reference Kurtin PJ, Dewald GW, Shields DJ, Hanson CA (1996) Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol 106:680–688PubMed Kurtin PJ, Dewald GW, Shields DJ, Hanson CA (1996) Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol 106:680–688PubMed
45.
go back to reference Parlier V, Van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, Bellomo HJ (1994) Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 78:219–231PubMedCrossRef Parlier V, Van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, Bellomo HJ (1994) Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 78:219–231PubMedCrossRef
46.
go back to reference Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8:67–71PubMed Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8:67–71PubMed
47.
go back to reference Falzetti D, Vermeesch JR, Hood TL, Nacheva EP, Matteucci C, Martelli MF, Van den Berghe H, Marynen P, Mecucci C (1999) Identification of multiple copies of a 20q−chromosome in a case of myelodysplastic syndrome: a FISH study. Leukemia Research 23:407–413PubMedCrossRef Falzetti D, Vermeesch JR, Hood TL, Nacheva EP, Matteucci C, Martelli MF, Van den Berghe H, Marynen P, Mecucci C (1999) Identification of multiple copies of a 20q−chromosome in a case of myelodysplastic syndrome: a FISH study. Leukemia Research 23:407–413PubMedCrossRef
48.
go back to reference Li T, Xue Y, Wu Y, Pan J (2004) Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q−). Br J Haematol 125:337–342PubMedCrossRef Li T, Xue Y, Wu Y, Pan J (2004) Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q−). Br J Haematol 125:337–342PubMedCrossRef
Metadata
Title
Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions
Authors
Nathalie Douet-Guilbert
Audrey Basinko
Frédéric Morel
Marie-Josée Le Bris
Valérie Ugo
Patrick Morice
Christian Berthou
Marc De Braekeleer
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0462-3

Other articles of this Issue 7/2008

Annals of Hematology 7/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine